WVP
PGNX

Worth Venture Partners’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Worth Venture Partners’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-32,956
Closed -$167K – 117
2019
Q3 		$167K Sell
32,956
-105,401
-76% -$526K 0.1% 73
2019
Q2 		$853K Hold
138,357
– – 0.47% 29
2019
Q1 		$641K Buy
138,357
+62,157
+82% +$281K 0.36% 37
2018
Q4 		$318K Buy
76,200
+61,200
+408% +$312K 0.24% 57
2018
Q3 		$94K Buy
+15,000
New +$115K 0.07% 102

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Worth Venture Partners's PGNX Position: Q4 2019 in Review

Worth Venture Partners sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 32,956 shares — an estimated $167K sold.

Worth Venture Partners first reported a position in PGNX in Q3 2018 and held it in 5 quarters. The position peaked at $853K in Q2 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Worth Venture Partners reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Worth Venture Partners sold 32,956 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $167K.
  • Worth Venture Partners first reported a position in Progenics Pharmaceuticals Inc in Q3 2018 and held it in 5 quarters.
  • Worth Venture Partners's Progenics Pharmaceuticals Inc position peaked at $853K in Q2 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Worth Venture Partners's 13F filing for Q4 2019, filed 14 Feb 2020.